Literature DB >> 14585358

The tumor-suppressive functions of the human INK4A locus.

P Mathijs Voorhoeve1, Reuven Agami.   

Abstract

The INK4A locus is often inactivated in human cancer. INK4A encodes for p14ARF and p16INK4A that inhibit growth through p53 and pRb, respectively. We used RNA interference vectors in transformation assays of human primary cells to analyze tumor-suppressive functions. We first show that a concerted inactivation of pRb and p53 is required for transformation. We then demonstrate that loss of p14ARF enhances growth in a p53-dependent manner but has little tumorigenic effect. In contrast, suppression of p16INK4A expression does not affect cellular proliferation but synergizes with p53 loss to accelerate growth and cause transformation. Our results delineate the functions of the human INK4A genes in normal and tumorigenic growth.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14585358     DOI: 10.1016/s1535-6108(03)00223-x

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  80 in total

1.  TSPYL5 suppresses p53 levels and function by physical interaction with USP7.

Authors:  Mirjam T Epping; Lars A T Meijer; Oscar Krijgsman; Johannes L Bos; Pier Paolo Pandolfi; René Bernards
Journal:  Nat Cell Biol       Date:  2010-12-19       Impact factor: 28.824

2.  TLX1/HOX11-mediated disruption of primary thymocyte differentiation prior to the CD4+CD8+ double-positive stage.

Authors:  Bronwyn M Owens; Teresa S Hawley; Lisa M Spain; Kristi A Kerkel; Robert G Hawley
Journal:  Br J Haematol       Date:  2006-01       Impact factor: 6.998

3.  ING2 regulates the onset of replicative senescence by induction of p300-dependent p53 acetylation.

Authors:  Remy Pedeux; Sagar Sengupta; Jiang Cheng Shen; Oleg N Demidov; Shin'ichi Saito; Hitoshi Onogi; Kensuke Kumamoto; Stephen Wincovitch; Susan H Garfield; Mary McMenamin; Makoto Nagashima; Steven R Grossman; Ettore Appella; Curtis C Harris
Journal:  Mol Cell Biol       Date:  2005-08       Impact factor: 4.272

4.  The human synMuv-like protein LIN-9 is required for transcription of G2/M genes and for entry into mitosis.

Authors:  Lisa Osterloh; Björn von Eyss; Fabienne Schmit; Lena Rein; Denise Hübner; Birgit Samans; Stefanie Hauser; Stefan Gaubatz
Journal:  EMBO J       Date:  2006-12-07       Impact factor: 11.598

5.  A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation.

Authors:  Alexander D Boiko; Sarah Porteous; Olga V Razorenova; Vadim I Krivokrysenko; Bryan R Williams; Andrei V Gudkov
Journal:  Genes Dev       Date:  2006-01-15       Impact factor: 11.361

6.  The chemokine receptor CXCR4 and the metalloproteinase MT1-MMP are mutually required during melanoma metastasis to lungs.

Authors:  Rubén A Bartolomé; Sergio Ferreiro; María E Miquilena-Colina; Lorena Martínez-Prats; María L Soto-Montenegro; David García-Bernal; Juan J Vaquero; Reuven Agami; Rafael Delgado; Manuel Desco; Paloma Sánchez-Mateos; Joaquin Teixidó
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

Review 7.  Ras oncogenes: split personalities.

Authors:  Antoine E Karnoub; Robert A Weinberg
Journal:  Nat Rev Mol Cell Biol       Date:  2008-07       Impact factor: 94.444

8.  Reduced c-Myc signaling triggers telomere-independent senescence by regulating Bmi-1 and p16(INK4a).

Authors:  Isil Guney; Shirley Wu; John M Sedivy
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-28       Impact factor: 11.205

9.  Malignant transformation in a defined genetic background: proteome changes displayed by 2D-PAGE.

Authors:  Stephanie M Pütz; Fotini Vogiatzi; Thorsten Stiewe; Albert Sickmann
Journal:  Mol Cancer       Date:  2010-09-22       Impact factor: 27.401

10.  The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence.

Authors:  Sebastian Haferkamp; Sieu L Tran; Therese M Becker; Lyndee L Scurr; Richard F Kefford; Helen Rizos
Journal:  Aging (Albany NY)       Date:  2009-05-16       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.